[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Parks et al., 1999 - Google Patents

Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors

Parks et al., 1999

View PDF @Full View
Document ID
6756013123557045347
Author
Parks R
Bramson J
Wan Y
Addison C
Graham F
Publication year
Publication venue
Journal of virology

External Links

Snippet

We have analyzed transgene (lacZ) expression from a first-generation adenovirus (Ad) vector in comparison to helper-dependent (hd) Ads deleted for various portions of the viral coding sequences and generated by using the Cre/lox P helper-dependent system (RJ …
Continue reading at journals.asm.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition

Similar Documents

Publication Publication Date Title
Parks et al. Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors
Parks et al. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
Amalfitano et al. Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy
Amalfitano et al. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
Reddy et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector
Palmer et al. Helper-dependent adenoviral vectors for gene therapy
Pastore et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors
Schiedner et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
Parks Improvements in adenoviral vector technology: overcoming barriers for gene therapy.
Brough et al. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo
Morsy et al. Expanded-capacity adenoviral vectors—the helper-dependent vectors
Ehrhardt et al. A new adenoviral helper–dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo
Hofmann et al. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo
Schnell et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors
Christ et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response
Zhou et al. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted
CA2282812C (en) Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
AU727992B2 (en) Adenoviral vectors comprising a modified E4 region but retaining E4ORF3
Andrews et al. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII
Gorziglia et al. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3
Schiedner et al. Variables affecting in vivo performance of high-capacity adenovirus vectors
Chirmule et al. Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs
US6686196B2 (en) Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof
Rosewell et al. Helper-dependent adenoviral vectors
CA2280237A1 (en) An oncolytic/immunogenic complementary-adenoviral vector system